Erwinaze is an asparaginase enzyme which depletes asparagine level in the bloodstream. Asparagine helps in cell growth, and its removal from the blood inhibits the growth of cells associated with acute lymphoblastic leukemia.
The approval is backed by clinical studies in 630 ALL patients, which yielded a positive data.
EUSA Pharma Chief Medical Officer Tim Corn said the approval of Erwinaze represents its continued dedication in the field of oncology.